Xiaoxia Wu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Xiaoxia Wu has a total of 35 co-authors. Here are the top co-authors by number of shared publications:
- Huiying Qiu
Jiangsu Institute of Hematology, National Clinical Research Center for Hematologic Diseases, the First Affiliated Hospital of Soochow University, Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology, Soochow University, Suzhou, P.R. China
3 shared publications Jingsheng Hua
Jiangsu Institute of Hematology, National Clinical Research Center for Hematologic Diseases, the First Affiliated Hospital of Soochow University, Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology, Soochow University, Suzhou, P.R. China
3 shared publicationsLili Zhou
Jiangsu Institute of Hematology, National Clinical Research Center for Hematologic Diseases, the First Affiliated Hospital of Soochow University, Institute of Blood and Marrow Transplantation, Suzhou, China
3 shared publicationsDepei Wu
Jiangsu Institute of Hematology, National Clinical Research Center for Hematologic Diseases, the First Affiliated Hospital of Soochow University Suzhou China
2 shared publicationsJian Zhang
Jiangsu Institute of Hematology, National Clinical Research Center for Hematologic Diseases, the First Affiliated Hospital of Soochow University, Institute of Blood and Marrow Transplantation, Suzhou, China
2 shared publicationsLei Yu
College of Chemistry and Molecular Engineering, East China Normal University, Shanghai, People's Republic of China
2 shared publications
Latest Publications
- Open Access
- 6 September 2024
- Published by Wiley in Cancer Medicine
- Vol. 13 (17) , e70161
The combination of a tyrosine kinase inhibitor and blinatumomab in patients with Philadelphia chromosome–positive acute lymphoblastic leukemia or Philadelphia chromosome‐like acute lymphoblastic leukemia
Tyrosine kinase inhibitors (TKIs) have revolutionized Philadelphia chromosome‐positive (Ph+) acute lymphoblastic leukemia (ALL) treatment. The combination of blinatumomab and a TKI in the frontline setting has shown the safety and efficacy of the chemotherapy‐free treatment approach in patients with Ph + ALL. This retrospective analysis included 19 patients with Ph + ALL and Ph‐like ALL treated with the combination of blinatumomab and a TKI. Of the 14 newly diagnosed patients, the overall response, complete remission (CR), and molecular response (CMR) rates after one cycle of blinatumomab were 100% (10/10), 90% (9/10), and 57% (8/14), respectively. Of the five relapsed patients, the CR and CMR rates were 50% (2/4) and 40% (2/5). Blinatumomab in combination with TKIs is safe and effective and hence this combination therapy could be a viable therapeutic option in front‐line treatment of patients with Ph + ALL.
- 6 September 2024
- Published by Wiley in Cancer Medicine
- Vol. 13 (17) , e70161
Open AccessThe combination of a tyrosine kinase inhibitor and blinatumomab in patients with Philadelphia chromosome–positive acute lymphoblastic leukemia or Philadelphia chromosome‐like acute lymphoblastic leukemia
Tyrosine kinase inhibitors (TKIs) have revolutionized Philadelphia chromosome‐positive (Ph+) acute lymphoblastic leukemia (ALL) treatment. The combination of blinatumomab and a TKI in the frontline setting has shown the safety and efficacy of the chemotherapy‐free treatment approach in patients with Ph + ALL. This retrospective analysis included 19 patients with Ph + ALL and Ph‐like ALL treated with the combination of blinatumomab and a TKI. Of the 14 newly diagnosed patients, the overall response, complete remission (CR), and molecular response (CMR) rates after one cycle of blinatumomab were 100% (10/10), 90% (9/10), and 57% (8/14), respectively. Of the five relapsed patients, the CR and CMR rates were 50% (2/4) and 40% (2/5). Blinatumomab in combination with TKIs is safe and effective and hence this combination therapy could be a viable therapeutic option in front‐line treatment of patients with Ph + ALL.
- 24 November 2020
- Published by Springer Nature in Bone Marrow Transplantation
- Vol. 56 (5) , 1056-1064
Donor-derived anti-CD19 CAR T cells compared with donor lymphocyte infusion for recurrent B-ALL after allogeneic hematopoietic stem cell transplantation
The efficacy and safety of donor-derived anti-CD19 CAR T cells vs DLI for the management of relapsed B-cell acute lymphoblastic leukemia (B-ALL) after allo-hematopoietic stem cell transplantation (HSCT) remain unclear. Thirteen B-ALL patients with relapsed after allo-HSCT and thus were treated with donor-derived anti-CD19 CAR T-cell (study group). Fifteen B-ALL patients relapsed after allo-HSCT and thus were treated with DLI (DLI group). The rates of MRD-negative complete remission (61.5%) in the study group were significantly higher than those in the DLI group (13.3%) (p = 0.02). The complete remission duration in study group and DLI group were median 8.0 months (range, 3–25 months) and 4.4 months (range, 1–25 months; p = 0.026), respectively. The overall survival of patients in the study group was superior to that of the DLI group: 9.5 months (range,3–25 months) versus 5.5 months (range, 1–25 months; p = 0.030). One patient with grade 1 acute graft-versus-host disease (aGVHD) was identified in the study group. While five (33.3%) patients in the DLI group developed grades III–IV aGVHD. Three patients (23.07%) developed grade 3 or 4 cytokine release syndrome in the study group. This study suggested that donor-derived anti-CD19 CAR T-cell therapy is promising, safe, and potentially effective for relapsed B-ALL after allo-HSCT and may be superior to DLI.
- 24 November 2020
- Published by Springer Nature in Bone Marrow Transplantation
- Vol. 56 (5) , 1056-1064
Donor-derived anti-CD19 CAR T cells compared with donor lymphocyte infusion for recurrent B-ALL after allogeneic hematopoietic stem cell transplantation
The efficacy and safety of donor-derived anti-CD19 CAR T cells vs DLI for the management of relapsed B-cell acute lymphoblastic leukemia (B-ALL) after allo-hematopoietic stem cell transplantation (HSCT) remain unclear. Thirteen B-ALL patients with relapsed after allo-HSCT and thus were treated with donor-derived anti-CD19 CAR T-cell (study group). Fifteen B-ALL patients relapsed after allo-HSCT and thus were treated with DLI (DLI group). The rates of MRD-negative complete remission (61.5%) in the study group were significantly higher than those in the DLI group (13.3%) (p = 0.02). The complete remission duration in study group and DLI group were median 8.0 months (range, 3–25 months) and 4.4 months (range, 1–25 months; p = 0.026), respectively. The overall survival of patients in the study group was superior to that of the DLI group: 9.5 months (range,3–25 months) versus 5.5 months (range, 1–25 months; p = 0.030). One patient with grade 1 acute graft-versus-host disease (aGVHD) was identified in the study group. While five (33.3%) patients in the DLI group developed grades III–IV aGVHD. Three patients (23.07%) developed grade 3 or 4 cytokine release syndrome in the study group. This study suggested that donor-derived anti-CD19 CAR T-cell therapy is promising, safe, and potentially effective for relapsed B-ALL after allo-HSCT and may be superior to DLI.
- Open Access
- 3 April 2020
- Published by Wiley in British Journal of Haematology
- Vol. 189 (5) , E200-E204
Efficacy of venetoclax in combination with azacitidine followed by haploidentical transplantation in refractory acute myeloid leukaemia and mixed phenotype acute leukaemia
- 3 April 2020
- Published by Wiley in British Journal of Haematology
- Vol. 189 (5) , E200-E204
Open AccessEfficacy of venetoclax in combination with azacitidine followed by haploidentical transplantation in refractory acute myeloid leukaemia and mixed phenotype acute leukaemia
- Open Access
- 1 March 2020
- Published by Taylor & Francis in OncoTargets and Therapy
- Vol. ume 13, 2311-2317
Sequential Infusion of Anti-CD22 and Anti-CD19 Chimeric Antigen Receptor T Cells for a Pediatric Ph-Like B-ALL Patient That Relapsed After CART-Cell and Haplo-HSCT Therapy: A Case Report and Review of Literature
Pediatric Philadelphia chromosome-like (Ph-like) acute B-lymphoblastic leukemia (B-ALL), a high-risk subset of B-ALL characterized by a gene expression profile similar to that of Ph-positive ALL, has extremely poor outcome after a relapse following autologous chimeric antigen receptor (CAR)-T and haploidentical (haplo) hematopoietic stem cell transplantation(HSCT)therapy. with very limited treatment options. Donor-derived CAR T-cell therapy, the most vital advanced anticancer technology, may be a promising salvage strategy for patients with Ph-like B-ALL. Here, we presented a relapsed and refractory case of a child with Ph-like B-ALL after autologous anti-CD19 CAR T-cell therapy followed by haplo-HSCT. She successfully achieved the fourth complete remission (CR4) and maintained CR for five months after the sequential infusion of donor-derived anti-CD22 and anti-CD19 CAR T cells, with mild CRS side effects and no obvious graft-versus-host disease. A donor-derived anti-CD22 and -CD19 CAR T-cell therapy combined with a sequential infusion strategy may provide a promising alternative treatment strategy as effective and safe salvage therapy for children with recurrent and refractory Ph-like B-ALL after autologous CD19-directed CAR T-cell therapy followed by haplo-HSCT.
- 1 March 2020
- Published by Taylor & Francis in OncoTargets and Therapy
- Vol. ume 13, 2311-2317
Open AccessSequential Infusion of Anti-CD22 and Anti-CD19 Chimeric Antigen Receptor T Cells for a Pediatric Ph-Like B-ALL Patient That Relapsed After CART-Cell and Haplo-HSCT Therapy: A Case Report and Review of Literature
Pediatric Philadelphia chromosome-like (Ph-like) acute B-lymphoblastic leukemia (B-ALL), a high-risk subset of B-ALL characterized by a gene expression profile similar to that of Ph-positive ALL, has extremely poor outcome after a relapse following autologous chimeric antigen receptor (CAR)-T and haploidentical (haplo) hematopoietic stem cell transplantation(HSCT)therapy. with very limited treatment options. Donor-derived CAR T-cell therapy, the most vital advanced anticancer technology, may be a promising salvage strategy for patients with Ph-like B-ALL. Here, we presented a relapsed and refractory case of a child with Ph-like B-ALL after autologous anti-CD19 CAR T-cell therapy followed by haplo-HSCT. She successfully achieved the fourth complete remission (CR4) and maintained CR for five months after the sequential infusion of donor-derived anti-CD22 and anti-CD19 CAR T cells, with mild CRS side effects and no obvious graft-versus-host disease. A donor-derived anti-CD22 and -CD19 CAR T-cell therapy combined with a sequential infusion strategy may provide a promising alternative treatment strategy as effective and safe salvage therapy for children with recurrent and refractory Ph-like B-ALL after autologous CD19-directed CAR T-cell therapy followed by haplo-HSCT.
- Open Access
- 1 January 2020
- Published by Taylor & Francis in OncoTargets and Therapy
- Vol. 13, 3045
Sequential Infusion of Anti-CD22 and Anti-CD19 Chimeric Antigen Receptor T Cells for a Pediatric Ph-Like B-ALL Patient That Relapsed After CART-Cell and Haplo-HSCT Therapy: A Case Report and Review of Literature (vol 13, pg 2311, 2020)
Sequential Infusion of Anti-CD22 and Anti-CD19 Chimeric Antigen Receptor T Cells for a Pediatric Ph-Like B-ALL Patient That Relapsed After CART-Cell and Haplo-HSCT Therapy: A Case Report and Review of Literature [Corrigendum] Hua J, Qian W, Wu X, et al. Onco Targets Ther. 2020;13:2311–2317. The authors of this paper have advised that the author and affiliation list on page 2311 is incorrect. The correct author and affiliation list is as follows:Jingsheng Hua1,2,*Weiqing Qian3,*Xiaoxia Wu1,*Lili Zhou1Lei Yu4Suning Chen1Jian Zhang1Huiying Qiu11Jiangsu Institute of Hematology, National Clinical Research Center for Hematologic Diseases, The First Affiliated Hospital of Soochow University, Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology, Soochow University, Suzhou 215006, Jiangsu, People’s Republic of China; 2Department of Hematology, Taizhou Municipal Hospital, Taizhou 318000, Zhejiang, People’s Republic of China; 3Suzhou Vocational Health College, Suzhou, Jiangsu, People’s Republic ofChina; 4College of Chemistry andMolecular Engineering, East China Normal University, Shanghai, People’s Republic of China*These authors contributed equally to this workThe authors have also advised that the correspondence section on page 2311 is incorrect. The correspondence section shouldread as follows:Correspondence: Huiying Qiu; Jian ZhangTel +8613912792913Fax +8651267781850Email qiuhuiying8303@suda.edu.cn; crystalzj06@163.comRead the original article
- 1 January 2020
- Published by Taylor & Francis in OncoTargets and Therapy
- Vol. 13, 3045
Open AccessSequential Infusion of Anti-CD22 and Anti-CD19 Chimeric Antigen Receptor T Cells for a Pediatric Ph-Like B-ALL Patient That Relapsed After CART-Cell and Haplo-HSCT Therapy: A Case Report and Review of Literature (vol 13, pg 2311, 2020)
Sequential Infusion of Anti-CD22 and Anti-CD19 Chimeric Antigen Receptor T Cells for a Pediatric Ph-Like B-ALL Patient That Relapsed After CART-Cell and Haplo-HSCT Therapy: A Case Report and Review of Literature [Corrigendum] Hua J, Qian W, Wu X, et al. Onco Targets Ther. 2020;13:2311–2317. The authors of this paper have advised that the author and affiliation list on page 2311 is incorrect. The correct author and affiliation list is as follows:Jingsheng Hua1,2,*Weiqing Qian3,*Xiaoxia Wu1,*Lili Zhou1Lei Yu4Suning Chen1Jian Zhang1Huiying Qiu11Jiangsu Institute of Hematology, National Clinical Research Center for Hematologic Diseases, The First Affiliated Hospital of Soochow University, Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology, Soochow University, Suzhou 215006, Jiangsu, People’s Republic of China; 2Department of Hematology, Taizhou Municipal Hospital, Taizhou 318000, Zhejiang, People’s Republic of China; 3Suzhou Vocational Health College, Suzhou, Jiangsu, People’s Republic ofChina; 4College of Chemistry andMolecular Engineering, East China Normal University, Shanghai, People’s Republic of China*These authors contributed equally to this workThe authors have also advised that the correspondence section on page 2311 is incorrect. The correspondence section shouldread as follows:Correspondence: Huiying Qiu; Jian ZhangTel +8613912792913Fax +8651267781850Email qiuhuiying8303@suda.edu.cn; crystalzj06@163.comRead the original article
- 25 April 2019
- Published by Springer Nature
- p. 543-549
Research on the Development Trend and Coping Strategies of Internet Finance
- 25 April 2019
- Published by Springer Nature
- p. 543-549
Research on the Development Trend and Coping Strategies of Internet Finance
- Open Access
- 1 January 2017
- Published by Atlantis Press SARL
Exploration on Educational Mechanism of Innovation and Entrepreneurship in Colleges and Universities
- 1 January 2017
- Published by Atlantis Press SARL
Open AccessExploration on Educational Mechanism of Innovation and Entrepreneurship in Colleges and Universities
- 1 March 2014
- Published by Elsevier in Transplant Immunology
- Vol. 30 (2-3) , 71-75
Mannose-binding lectin-2 and ficolin-2 gene polymorphisms and clinical risk factors for acute rejection in kidney transplantation
- 1 March 2014
- Published by Elsevier in Transplant Immunology
- Vol. 30 (2-3) , 71-75
Mannose-binding lectin-2 and ficolin-2 gene polymorphisms and clinical risk factors for acute rejection in kidney transplantation